サマリー

市場の分析と洞察。不活性化インフルエンザワクチンの世界市場
COVID-19のパンデミックにより、不活化インフルエンザワクチンの世界市場規模は2022年に百万米ドルと推定され、レビュー期間中にCAGR %で2028年までに百万米ドルの再調整サイズになると予測されています。この健康危機による経済変化を十分に考慮し、2021年に不活化インフルエンザワクチン世界市場の%を占めた3価インフルエンザワクチンは、2028年までに100万米ドルの価値を持ち、COVID-19以降の期間に修正された% CAGRで成長すると予測されます。一方、小児用セグメントは、この予測期間を通じて、% CAGRに変更されています。
中国の不活化インフルエンザワクチン市場規模は2021年に百万米ドル、米国と欧州の不活化インフルエンザワクチンはそれぞれ百万米ドル、百万米ドルと評価されています。2021年の米国の比率は％、中国と欧州はそれぞれ％と％で、中国の比率は2028年には％に達すると予測され、分析期間を通じてCAGRは％となっています。日本、韓国、東南アジアはアジアで注目すべき市場であり、今後6年間のCAGRはそれぞれ％、％、％となっています。ヨーロッパの不活化インフルエンザワクチン市場については、ドイツが2028年までに100万ドルに達すると予測され、予測期間中のCAGRは%となっています。
不活化インフルエンザワクチンの世界的な主要メーカーは、CSL Limited、GSK、Sanofi Pasteur、Viatris、Hualan Biological、AstraZeneca、Sinovac Biotech、Aleph Biomedical、Abbott Laboratoriesなどです。2021年、世界の上位5社は売上高で約 %のシェアを占めています。

世界の不活化インフルエンザワクチンの範囲とセグメント
不活化インフルエンザワクチン市場は、タイプ別、用途別に分類されます。世界の不活化インフルエンザワクチン市場におけるプレイヤー、ステークホルダー、その他の参加者は、本レポートを強力なリソースとして利用することで、優位に立つことができるでしょう。セグメント別分析では、2017年から2028年までのタイプ別、アプリケーション別の売上、収益、予測に焦点を当てています。

タイプ別セグメント
3価インフルエンザワクチン
4価インフルエンザワクチン
用途別セグメント
小児
青少年期
成人
高齢者
会社別
CSL社
GSK
サノフィパスツール
ビアトリス
華蘭生物学
アストラゼネカ
シノバクバイオテック
アレフバイオメディカル
アボット・ラボラトリーズ
ノバルティスインターナショナル
地域別
北米
米国
カナダ
欧州
ドイツ
フランス
イギリス
イタリア
ロシア
アジア太平洋地域
中国
日本
韓国
インド
オーストラリア
中国 台湾
インドネシア
タイ
マレーシア
中南米
メキシコ
ブラジル
アルゼンチン
コロンビア
中東・アフリカ
トルコ
サウジアラビア
UAE

ページTOPに戻る

目次

1 Study Coverage
1.1 Inactivated Influenza Vaccine Product Introduction
1.2 Market by Type
1.2.1 Global Inactivated Influenza Vaccine Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 Trivalent Influenza Vaccine
1.2.3 Quadrivalent Influenza Vaccine
1.3 Market by Application
1.3.1 Global Inactivated Influenza Vaccine Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Children
1.3.3 Adolescence
1.3.4 Adults
1.3.5 Elderly
1.4 Study Objectives
1.5 Years Considered
2 Executive Summary
2.1 Global Inactivated Influenza Vaccine Sales Estimates and Forecasts 2017-2028
2.2 Global Inactivated Influenza Vaccine Revenue Estimates and Forecasts 2017-2028
2.3 Global Inactivated Influenza Vaccine Revenue by Region: 2017 VS 2021 VS 2028
2.4 Global Inactivated Influenza Vaccine Sales by Region
2.4.1 Global Inactivated Influenza Vaccine Sales by Region (2017-2022)
2.4.2 Global Sales Inactivated Influenza Vaccine by Region (2023-2028)
2.5 Global Inactivated Influenza Vaccine Revenue by Region
2.5.1 Global Inactivated Influenza Vaccine Revenue by Region (2017-2022)
2.5.2 Global Inactivated Influenza Vaccine Revenue by Region (2023-2028)
2.6 North America
2.7 Europe
2.8 Asia-Pacific
2.9 Latin America
2.10 Middle East & Africa
3 Competition by Manufacturers
3.1 Global Inactivated Influenza Vaccine Sales by Manufacturers
3.1.1 Global Top Inactivated Influenza Vaccine Manufacturers by Sales (2017-2022)
3.1.2 Global Inactivated Influenza Vaccine Sales Market Share by Manufacturers (2017-2022)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Inactivated Influenza Vaccine in 2021
3.2 Global Inactivated Influenza Vaccine Revenue by Manufacturers
3.2.1 Global Inactivated Influenza Vaccine Revenue by Manufacturers (2017-2022)
3.2.2 Global Inactivated Influenza Vaccine Revenue Market Share by Manufacturers (2017-2022)
3.2.3 Global Top 10 and Top 5 Companies by Inactivated Influenza Vaccine Revenue in 2021
3.3 Global Inactivated Influenza Vaccine Sales Price by Manufacturers (2017-2022)
3.4 Analysis of Competitive Landscape
3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Inactivated Influenza Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4.3 Global Inactivated Influenza Vaccine Manufacturers Geographical Distribution
3.5 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global Inactivated Influenza Vaccine Sales by Type
4.1.1 Global Inactivated Influenza Vaccine Historical Sales by Type (2017-2022)
4.1.2 Global Inactivated Influenza Vaccine Forecasted Sales by Type (2023-2028)
4.1.3 Global Inactivated Influenza Vaccine Sales Market Share by Type (2017-2028)
4.2 Global Inactivated Influenza Vaccine Revenue by Type
4.2.1 Global Inactivated Influenza Vaccine Historical Revenue by Type (2017-2022)
4.2.2 Global Inactivated Influenza Vaccine Forecasted Revenue by Type (2023-2028)
4.2.3 Global Inactivated Influenza Vaccine Revenue Market Share by Type (2017-2028)
4.3 Global Inactivated Influenza Vaccine Price by Type
4.3.1 Global Inactivated Influenza Vaccine Price by Type (2017-2022)
4.3.2 Global Inactivated Influenza Vaccine Price Forecast by Type (2023-2028)
5 Market Size by Application
5.1 Global Inactivated Influenza Vaccine Sales by Application
5.1.1 Global Inactivated Influenza Vaccine Historical Sales by Application (2017-2022)
5.1.2 Global Inactivated Influenza Vaccine Forecasted Sales by Application (2023-2028)
5.1.3 Global Inactivated Influenza Vaccine Sales Market Share by Application (2017-2028)
5.2 Global Inactivated Influenza Vaccine Revenue by Application
5.2.1 Global Inactivated Influenza Vaccine Historical Revenue by Application (2017-2022)
5.2.2 Global Inactivated Influenza Vaccine Forecasted Revenue by Application (2023-2028)
5.2.3 Global Inactivated Influenza Vaccine Revenue Market Share by Application (2017-2028)
5.3 Global Inactivated Influenza Vaccine Price by Application
5.3.1 Global Inactivated Influenza Vaccine Price by Application (2017-2022)
5.3.2 Global Inactivated Influenza Vaccine Price Forecast by Application (2023-2028)
6 North America
6.1 North America Inactivated Influenza Vaccine Market Size by Type
6.1.1 North America Inactivated Influenza Vaccine Sales by Type (2017-2028)
6.1.2 North America Inactivated Influenza Vaccine Revenue by Type (2017-2028)
6.2 North America Inactivated Influenza Vaccine Market Size by Application
6.2.1 North America Inactivated Influenza Vaccine Sales by Application (2017-2028)
6.2.2 North America Inactivated Influenza Vaccine Revenue by Application (2017-2028)
6.3 North America Inactivated Influenza Vaccine Market Size by Country
6.3.1 North America Inactivated Influenza Vaccine Sales by Country (2017-2028)
6.3.2 North America Inactivated Influenza Vaccine Revenue by Country (2017-2028)
6.3.3 United States
6.3.4 Canada
7 Europe
7.1 Europe Inactivated Influenza Vaccine Market Size by Type
7.1.1 Europe Inactivated Influenza Vaccine Sales by Type (2017-2028)
7.1.2 Europe Inactivated Influenza Vaccine Revenue by Type (2017-2028)
7.2 Europe Inactivated Influenza Vaccine Market Size by Application
7.2.1 Europe Inactivated Influenza Vaccine Sales by Application (2017-2028)
7.2.2 Europe Inactivated Influenza Vaccine Revenue by Application (2017-2028)
7.3 Europe Inactivated Influenza Vaccine Market Size by Country
7.3.1 Europe Inactivated Influenza Vaccine Sales by Country (2017-2028)
7.3.2 Europe Inactivated Influenza Vaccine Revenue by Country (2017-2028)
7.3.3 Germany
7.3.4 France
7.3.5 U.K.
7.3.6 Italy
7.3.7 Russia
8 Asia Pacific
8.1 Asia Pacific Inactivated Influenza Vaccine Market Size by Type
8.1.1 Asia Pacific Inactivated Influenza Vaccine Sales by Type (2017-2028)
8.1.2 Asia Pacific Inactivated Influenza Vaccine Revenue by Type (2017-2028)
8.2 Asia Pacific Inactivated Influenza Vaccine Market Size by Application
8.2.1 Asia Pacific Inactivated Influenza Vaccine Sales by Application (2017-2028)
8.2.2 Asia Pacific Inactivated Influenza Vaccine Revenue by Application (2017-2028)
8.3 Asia Pacific Inactivated Influenza Vaccine Market Size by Region
8.3.1 Asia Pacific Inactivated Influenza Vaccine Sales by Region (2017-2028)
8.3.2 Asia Pacific Inactivated Influenza Vaccine Revenue by Region (2017-2028)
8.3.3 China
8.3.4 Japan
8.3.5 South Korea
8.3.6 India
8.3.7 Australia
8.3.8 China Taiwan
8.3.9 Indonesia
8.3.10 Thailand
8.3.11 Malaysia
9 Latin America
9.1 Latin America Inactivated Influenza Vaccine Market Size by Type
9.1.1 Latin America Inactivated Influenza Vaccine Sales by Type (2017-2028)
9.1.2 Latin America Inactivated Influenza Vaccine Revenue by Type (2017-2028)
9.2 Latin America Inactivated Influenza Vaccine Market Size by Application
9.2.1 Latin America Inactivated Influenza Vaccine Sales by Application (2017-2028)
9.2.2 Latin America Inactivated Influenza Vaccine Revenue by Application (2017-2028)
9.3 Latin America Inactivated Influenza Vaccine Market Size by Country
9.3.1 Latin America Inactivated Influenza Vaccine Sales by Country (2017-2028)
9.3.2 Latin America Inactivated Influenza Vaccine Revenue by Country (2017-2028)
9.3.3 Mexico
9.3.4 Brazil
9.3.5 Argentina
9.3.6 Colombia
10 Middle East and Africa
10.1 Middle East and Africa Inactivated Influenza Vaccine Market Size by Type
10.1.1 Middle East and Africa Inactivated Influenza Vaccine Sales by Type (2017-2028)
10.1.2 Middle East and Africa Inactivated Influenza Vaccine Revenue by Type (2017-2028)
10.2 Middle East and Africa Inactivated Influenza Vaccine Market Size by Application
10.2.1 Middle East and Africa Inactivated Influenza Vaccine Sales by Application (2017-2028)
10.2.2 Middle East and Africa Inactivated Influenza Vaccine Revenue by Application (2017-2028)
10.3 Middle East and Africa Inactivated Influenza Vaccine Market Size by Country
10.3.1 Middle East and Africa Inactivated Influenza Vaccine Sales by Country (2017-2028)
10.3.2 Middle East and Africa Inactivated Influenza Vaccine Revenue by Country (2017-2028)
10.3.3 Turkey
10.3.4 Saudi Arabia
11 Company Profiles
11.1 CSL Limited
11.1.1 CSL Limited Corporation Information
11.1.2 CSL Limited Overview
11.1.3 CSL Limited Inactivated Influenza Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.1.4 CSL Limited Inactivated Influenza Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 CSL Limited Recent Developments
11.2 GSK
11.2.1 GSK Corporation Information
11.2.2 GSK Overview
11.2.3 GSK Inactivated Influenza Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.2.4 GSK Inactivated Influenza Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 GSK Recent Developments
11.3 Sanofi Pasteur
11.3.1 Sanofi Pasteur Corporation Information
11.3.2 Sanofi Pasteur Overview
11.3.3 Sanofi Pasteur Inactivated Influenza Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.3.4 Sanofi Pasteur Inactivated Influenza Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 Sanofi Pasteur Recent Developments
11.4 Viatris
11.4.1 Viatris Corporation Information
11.4.2 Viatris Overview
11.4.3 Viatris Inactivated Influenza Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.4.4 Viatris Inactivated Influenza Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 Viatris Recent Developments
11.5 Hualan Biological
11.5.1 Hualan Biological Corporation Information
11.5.2 Hualan Biological Overview
11.5.3 Hualan Biological Inactivated Influenza Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.5.4 Hualan Biological Inactivated Influenza Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 Hualan Biological Recent Developments
11.6 AstraZeneca
11.6.1 AstraZeneca Corporation Information
11.6.2 AstraZeneca Overview
11.6.3 AstraZeneca Inactivated Influenza Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.6.4 AstraZeneca Inactivated Influenza Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 AstraZeneca Recent Developments
11.7 Sinovac Biotech
11.7.1 Sinovac Biotech Corporation Information
11.7.2 Sinovac Biotech Overview
11.7.3 Sinovac Biotech Inactivated Influenza Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.7.4 Sinovac Biotech Inactivated Influenza Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.7.5 Sinovac Biotech Recent Developments
11.8 Aleph Biomedical
11.8.1 Aleph Biomedical Corporation Information
11.8.2 Aleph Biomedical Overview
11.8.3 Aleph Biomedical Inactivated Influenza Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.8.4 Aleph Biomedical Inactivated Influenza Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.8.5 Aleph Biomedical Recent Developments
11.9 Abbott Laboratories
11.9.1 Abbott Laboratories Corporation Information
11.9.2 Abbott Laboratories Overview
11.9.3 Abbott Laboratories Inactivated Influenza Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.9.4 Abbott Laboratories Inactivated Influenza Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.9.5 Abbott Laboratories Recent Developments
11.10 Novartis International
11.10.1 Novartis International Corporation Information
11.10.2 Novartis International Overview
11.10.3 Novartis International Inactivated Influenza Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.10.4 Novartis International Inactivated Influenza Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.10.5 Novartis International Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Inactivated Influenza Vaccine Industry Chain Analysis
12.2 Inactivated Influenza Vaccine Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Inactivated Influenza Vaccine Production Mode & Process
12.4 Inactivated Influenza Vaccine Sales and Marketing
12.4.1 Inactivated Influenza Vaccine Sales Channels
12.4.2 Inactivated Influenza Vaccine Distributors
12.5 Inactivated Influenza Vaccine Customers
13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis
13.1 Inactivated Influenza Vaccine Industry Trends
13.2 Inactivated Influenza Vaccine Market Drivers
13.3 Inactivated Influenza Vaccine Market Challenges
13.4 Inactivated Influenza Vaccine Market Restraints
14 Key Findings in The Global Inactivated Influenza Vaccine Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer